Quoin Pharmaceuticals, Ltd.
Nasdaq: QNRXPharmaceutical Preparations · Entity-resolved by Clous
CIK0001671502
TickerQNRX
ExchangeNasdaq
SIC2834
StateL3
FY end—
Key financials
Revenue
—
—
Net IncomeFY2025-12-31
-$15.8M
-76.3% YoY
Total AssetsFY2025-12-31
$20.39M
+29.8% YoY
EquityFY2025-12-31
$13.12M
+42.5% YoY
Shares OutstandingFY2025-12-31
3.35B
—
Operating Cash FlowFY2025-12-31
-$13.54M
-72.3% YoY
Market
Market
QNRXClose price
$4.67
Market cap
$15.67B
delayed EOD · as of 2026-06-18
Short interest & fails
Cost to borrow70.65%30K shares availablehard to borrow
Short-sale volume
FINRA Reg SHO · daily36.4%
short of total volume · 2026-06-18
2026-06-1836.4%
2026-06-1746.2%
2026-06-1643.3%
2026-06-1530.9%
2026-06-1223.8%
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The filing text is not provided, so the specific contents of Quoin Pharmaceuticals’ Form 10‑K cannot be determined.
What it means
Unable to assess significance without the filing details.
What to watch
Monitor for the actual 10‑K release or a summary from reliable sources.
Generated from public filings · not investment advice
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Net Income | -$9.38M | -$8.69M | -$8.96M | -$15.8M | -76.3% | — |
| Total Assets | $14.46M | $12.17M | $15.71M | $20.39M | +29.8% | — |
| Equity | $7.41M | $5.66M | $9.2M | $13.12M | +42.5% | — |
| Operating Cash Flow | -$8.48M | -$7.86M | -$7.86M | -$13.54M | -72.3% | — |
| Shares Outstanding | — | — | — | 3.35B | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001671502